Tested Applications
| Positive IHC detected in | human kidney tissue, human breast cancer tissue, mouse embryo tissue, mouse lung tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
21933-1-AP targets SOST/Sclerostin in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag16567 Product name: Recombinant human SOST protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 36-213 aa of BC101086 Sequence: IIPELGEYPEPPPELENNKTMNRAENGGRPPHHPFETKDVSEYSCRELHFTRYVTDGPCRSAKPVTELVCSGQCGPARLLPNAIGRGKWWRPSGPDFRCIPDRYRAQRVQLLCPGGEAPRARKVRLVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY Predict reactive species |
| Full Name | sclerosteosis |
| Calculated Molecular Weight | 213 aa, 24 kDa |
| GenBank Accession Number | BC101086 |
| Gene Symbol | Sclerostin |
| Gene ID (NCBI) | 50964 |
| RRID | AB_2878947 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9BQB4 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for SOST/Sclerostin antibody 21933-1-AP | Download protocol |
| IHC protocol for SOST/Sclerostin antibody 21933-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
Anti-SOST/Sclerostin (cat. no. 21933-1-AP) has 29 citations spanning 27 journals, including Cell Metabolism, Redox Biology, EMBO Molecular Medicine, FASEB Journal, International Journal of Biological Sciences, Phytomedicine, and Biochemical Pharmacology. Research fields cover bone metabolism and osteoporosis, chronic kidney disease, vascular biology, cardiac repair, orthodontics and dental biology, oncology (uveal melanoma, myelofibrosis), and diabetes-related bone loss.
| Species | Application | Title |
|---|---|---|
Cell Metab An integrated multi-omics analysis reveals osteokines involved in global regulation | ||
Redox Biol Activation of sclerostin inhibits Isg20-Mediated aerobic glycolysis ameliorating renal Fibrosis: the renoprotective mechanism of hederagenin in CKD | ||
Redox Biol Insights into taurine therapy for periodontitis: Targeting osteocyte ferroptosis to mitigate obesity-exacerbated bone damage. | ||
Int J Biol Sci Colchicine Blocks Abdominal Aortic Aneurysm Development by Maintaining Vascular Smooth Muscle Cell Homeostasis | ||
Phytomedicine Capture the superior anti-osteoporotic innovative multi-component complex from Ligustri Lucidi Fructus based on Component Recombination strategy. | ||
Mater Today Bio Self-assembled extracellular matrix-lipid nanoparticle composite for site-specific siRNA delivery to improve cardiac repair post-myocardial infarction. |
